Literature DB >> 15242256

AE-941 (AEterna).

Keith Dredge1.   

Abstract

AEterna is developing AE-941, an angiogenesis inhibitor derived from the ultrafiltration of liquid shark cartilage, with matrix metalloprotease (MMP)-2, MMP-9 and vascular endothelial growth factor inhibitory properties, for the potential treatment of non-small-cell lung cancer.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15242256

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

1.  Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats.

Authors:  Jing-Wei Mao; Xiao-Mei He; Hai-Ying Tang; Ying-De Wang
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

Review 2.  Bioactive Peptide of Marine Origin for the Prevention and Treatment of Non-Communicable Diseases.

Authors:  Ratih Pangestuti; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2017-03-09       Impact factor: 5.118

3.  Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases.

Authors:  Eyal Zcharia; Juan Jia; Xiao Zhang; Lea Baraz; Ulf Lindahl; Tamar Peretz; Israel Vlodavsky; Jin-Ping Li
Journal:  PLoS One       Date:  2009-04-10       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.